A comprehensive characterization of the peptide and protein constituents of human seminal fluid

Prostate

Volumn 61, Issue 2, 2004, Pages 171-181

  Fung, Kim Y C ^a   Glode, L Michael ^a   Green, Spencer ^a   Duncan, Mark W ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Biomarkers; Peptides; Prostate cancer; Proteins; Proteomics; PSA

Indexed keywords

GROWTH FACTOR; HORMONE; PEPTIDE;

ARTICLE; DISEASE MARKER; GEL ELECTROPHORESIS; HUMAN; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE DISEASE; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEOMICS; SEMINAL PLASMA; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ELECTROPHORESIS; HUMANS; MALE; MASS SPECTROMETRY; PEPTIDES; PROTEINS; PROTEOMICS; SEMEN;

EID: 4544225278     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20089     Document Type: Article

References (61)

1. Cancer facts and figures 2002. American Cancer Society, Inc. 2002. pp 3-15.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
3. Brawley OW, Barnes S, Parnes H. The future of prostate cancer prevention. Ann NY Acad Sci 2001;952:145-152.
4. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-67.
5. Hamdy FC, Thomas BG. New therapeutic concepts in prostate cancer. BJU Int 2001;88(Suppl 2):43-48; discussion 49-50.
6. Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer 1996;77:2162-2166.
7. Thompson I, Carroll P, Coley C, Sweat G, McLeod D, Schelhammer P, Wasson J, Zietman A, Schwartz C. The PSA best practices policy of the American Urological Association. AUA Update Series 2001;9:66-71.
8. Smith DS, Carvalhal GF, Mager DE, Bullock AD, Catalona WL, Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 1998;160:1734-1738.
9. Physicians, ACo. Screening for prostate cancer. Ann Int Med 1991;126:480-484.
10. Okegawa T, Noda H, Nutahara K, Higashihara E. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. Urology 2000;55:700-704.
11. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
12. James P, Quadroni M, Carafoli E, Gonnet G. Protein identification by mass profile fingerprinting. Biochem Biophys Res Commun 1993;195:58-64.
13. Mann M, Hojrup P, Roepstorff P. Use of mass spectrometric molecular weight information to identify proteins in sequence databases. Biol Mass Spectrom 1993;22:338-345.
14. McCormack AL, Schieltz DM, Goode B, Yang S, Barnes G, Drubin D, Yates JR III. Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Anal Chem 1997;69:767-776.
15. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF III, Emmert-Buck MR. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 2000;21:2235-2242.
16. Ahram M, Best CJ, Flaig MJ, Gillespie JW, Leiva IM, Chuaqui RF, Zhou G, Shu H, Duray PH, Linehan WM, Raffeld M, Ornstein DK, Zhao Y, Petricoin EF III, Emmert-Buck MR. Proteomic analysis of human prostate cancer. Mol Carcinog 2002;33:9-15.
17. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002;50:54-63.
18. Paweletz CP, Liotta LA, Petricoin EF III. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 2001;57:160-163.
19. Alaiya AA, Oppermann M, Langridge J, Roblick U, Egevad L, Brindstedt S, Hellstrom M, Linder S, Bergman T, Jornvall H, Auer G. Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry. Cell Mol Life Sci 2001;58:307-311.
20. Alaiya A, Roblick U, Egevad L, Carlsson A, Franzen B, Volz D, Huwendiek S, Linder S, Auer G. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 2000;21:1-9.
21. Charrier JP, Tournel C, Michel S, Comby S, Jolivet-Reynaud C, Passagot J, Dalbon P, Chautard D, Jolivet M. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Electrophoresis 2001;22:1861-1866.
22. Starita-Geribaldi M, Poggioli S, Zucchini M, Garin J, Chevallier D, Fenichel P, Pointis G. Mapping of seminal plasma proteins by two-dimensional gel electrophoresis in men with normal and impaired spermatogenesis. Mol Hum Reprod 2001;7:715-722.
23. Ayyagari RR, Fazleabas AT, Dawood MY. Seminal plasma proteins of fertile and infertile men analyzed by two-dimensional electrophoresis. Am J Obstet Gynecol 1987;157:1528-1533.
24. Tsai YC, Harrison HH, Lee C, Daufeldt JA, Oliver L, Grayhack J. Systematic characterization of human prostatic fluid proteins with two-dimensional electrophoresis. Clin Chem 1984;30:2026-2030.
25. Taga EM, Moore DL, Van Etten RL. Studies on the structural basis of the heterogeneity of human prostatic and seminal acid phosphatases. Prostate 1983;4:141-150.
26. Wang TJ, Linton HJ, Sokoloff RL, Grauer LS, Rittenhouse HG, Wolfert RL. Western blotting analysis of antibodies to prostate-specific antigen: Specificities for prostate-specific antigen and prostate-specific antigen fragments. Tumour Biol 1999;20:79-85.
27. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fiuid. Clin Chem 1995;41:1567-1573.
28. Belanger A, van Halbeek H, Graves HC, Grandbois K, Stamey TA, Huang L, Poppe I, Labrie F. Molecular mass and carbohydrate structure of prostate specific antigen: Studies for establishment of an international PSA standard. Prostate 1995;27:187-197.
29. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, Evans CL, Gasior CL, Linton HJ, Carpenter P, Rittenhouse HG. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61:6958-6963.
30. Ward AM, Catto JW, Hamdy FC. Prostate specific antigen: Biology, biochemistry, and available commercial assays. Ann Clin Biochem 2001;38:633-651.
31. Jung K, Stephan C, Elgeti U, Lein M, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA, Sinha P. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 μg/L: Are they useful tools for early detection and screening of prostate cancer? Int J Cancer 2001;93:759-765.
32. Bangma CH, Verhagen PC. Blood and serum substances for markers of prostate cancer. Microsc Res Tech 2000;51:430-435.
33. Peter A, Lilja H, Lundwall A, Malm J, Semenogelin I and semenogelin II, the major gel-forming proteins in human semen, are substrates for transglutaminase. Eur J Biochem 1998;252:216-221.
34. Malm J, Hellman J, Magnusson H, Laurell CB, Lilja H. Isolation and characterization of the major gel proteins in human semen, semenogelin I, and semenogelin II. Eur J Biochem 1996;238:48-53.
35. Robert M, Gagnon C. Semenogelin I: A coagulum forming, multifunctional seminal vesicle protein. Cell Mol Life Sci 1999;55:944-960.
36. Calabrese G, Sures I, Pompetti F, Natoli G, Palka G, Iacobelli S. The gene (LGALS3BP) encoding the serum protein 90K, associated with cancer and infection by the human immunodeficiency virus, maps at 17q25. Cytogenet Cell Genet 1995;69:223-225.
37. Jensen JA, Carroll RE, Benya RV. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001;22:689-699.
38. Reid WA, Liddle CN, Svasti J, Kay J. Gastricsin in the benign and malignant prostate. J Clin Pathol 1985;38:639-643.
39. Merino AM, Vazquez J, Rodriguez JC, Fernandez R, Quintela I, Gonzalez LO, Sanchez LM, Vizoso F. Pepsinogen C expression in tumors of extragastric origin. Int J Biol Markers 2000;15:165-170.
40. Konishi N, Nakaoka S, Matsumoto K, Nakamura M, Kuwashima S, Hiasa Y, Cho M, Uemura H, Hirao Y. Expression of pepsinogen II with androgen and estrogen receptors in human prostate carcinoma. Pathol Int 1999;49:203-207.
41. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, Shawver LK, Schlessinger J, Iacobelli S. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 1994;269:18401-18407.
42. Aprikian AG, Han K, Guy L, Landry F, Begin LR, Chevalier S. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate Suppl 1998;8:52-61.
43. Carroll RE, Matkowskyj KA, Chakrabarti S, McDonald TJ, Benya RV. Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am J Physiol 1999;276:G655-G665.
44. Zachary I, Woll PJ, Rozengurt E. A role for neuropeptides in the control of cell proliferation. Dev Biol 1987;124:295-308.
45. Woll PJ. Neuropeptide growth factors and cancer. Br J Cancer 1991;63:469-475.
46. Kim S, Hu W, Kelly DR, Hellmich MR, Evers BM, Chung DH. Gastrin-releasing peptide is a growth factor for human neuroblastomas. Ann Surg 2002;235:621-629; discussion 629-630.
47. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 2000;42:295-303.
48. Bartholdi MF, Wu JM, Pu H, Troncoso P, Eden PA, Feldman RI. In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int J Cancer 1998;79:82-90.
49. Yashi M, Muraishi O, Kobayashi Y, Tokue A, Nanjo H. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients. Prostate 2002;51:84-97.
50. Cohen MK, Arber DA, Coffield KS, Keegan GT, McClintock J, Speights VO, Jr. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994;74:1899-1903.
51. Goverde HJ, Bisseling JG, Wetzels AM, Braat DD, Pesman GJ, Sweep FC, Meuleman EJ. A neuropeptide in human semen: Oxytocin. Arch Androl 1998;41:17-22.
52. O'Mahony OA, Djahanbahkch O, Mahmood T, Puddefoot JR, Vinson GP. Angiotensin II in human seminal fluid. Hum Reprod 2000;15:1345-1349.
53. Slavakis A, Papadimas J. Procalcitonin: Does it play a role in male reproduction? Fertil Steril 2000;74:1227-1228.
54. Odum L, Johnsen AH. Human seminal plasma contains somatostatin-64. Biochem J 1994;303:263-268.
55. Khan Z, Smyth DG. Isolation and identification of N-terminally extended forms of 5-oxoprolylglutamylprolinamide (Glp-Glu-Pro-NH2), a thyrotropin-releasing-hormone (TRH)-like peptide present in human semen. Eur J Biochem 1993;212:35-40.
56. Cockle SM, Aitken A, Beg F, Morrell JM, Smyth DG. The TRH-related peptide pyroglutamyglutamylprolinamide is present in human semen. FEBS Lett 1989;252:113-117.
57. Cockle SM, Prater GV, Thetford CR, Hamilton C, Malone PR, Mundy AR. Peptides related to thyrotrophin-releasing hormone (TRH) in human prostate and semen. Biochim Biophys Acta 1994;1227:60-66.
58. Gkonos PJ, Kwok CK, Block NL, Roos BA. Identification of the human seminal TRH-like peptide pGlu-Phe-Pro-NH2 in normal human prostate. Peptides 1994;15:1281-1283.
59. Malm J, Sorensen O, Persson T, Frohm-Nilsson M, Johansson B, Bjartell A, Lilja H, Stahle-Backdahl M, Borregaard N, Egesten A. The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun 2000;68:4297-4302.
60. Kravets FG, Lee J, Singh B, Trocchia A, Pentyala SN, Khan SA. Prostasomes: Current concepts. Prostate 2000;43:169-174.
61. Carlsson L, Pahlson C, Bergquist M, Ronquist G, Stridsberg M. Antibacterial activity of human prostasomes. Prostate 2000;44:279-286.